Long term outcome of patients with steroid-refractory acute intestinal graft versus host disease after treatment with pentostatin - PubMed

Long term outcome of patients with steroid-refractory acute intestinal graft versus host disease after treatment with pentostatin

Stefan A Klein et al. Br J Haematol. 2011 Jul.

Free article

Similar articles

• Pentostatin in steroid-refractory acute graft-versus-host disease.

  Bolaños-Meade J, Jacobsohn DA, Margolis J, Ogden A, Wientjes MG, Byrd JC, Lucas DM, Anders V, Phelps M, Grever MR, Vogelsang GB. Bolaños-Meade J, et al. J Clin Oncol. 2005 Apr 20;23(12):2661-8. doi: 10.1200/JCO.2005.06.130. J Clin Oncol. 2005. PMID: 15837980 Clinical Trial.

• Pentostatin as rescue therapy for glucocorticoid-refractory acute and chronic graft-versus-host disease.

  Pidala J, Kim J, Roman-Diaz J, Shapiro J, Nishihori T, Bookout R, Anasetti C, Kharfan-Dabaja MA. Pidala J, et al. Ann Transplant. 2010 Oct-Dec;15(4):21-9. Ann Transplant. 2010. PMID: 21183872

• Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease.

  Jacobsohn DA, Chen AR, Zahurak M, Piantadosi S, Anders V, Bolaños-Meade J, Higman M, Margolis J, Kaup M, Vogelsang GB. Jacobsohn DA, et al. J Clin Oncol. 2007 Sep 20;25(27):4255-61. doi: 10.1200/JCO.2007.10.8456. J Clin Oncol. 2007. PMID: 17878478 Clinical Trial.

• An old drug for a new disease: pentostatin (Nipent) in acute graft-versus-host disease.

  Margolis J, Vogelsang G. Margolis J, et al. Semin Oncol. 2000 Apr;27(2 Suppl 5):72-7. Semin Oncol. 2000. PMID: 10877057 Review.

• Pentostatin - pharmacology, immunology, and clinical effects in graft-versus-host disease.

  Higman M, Vogelsang GB, Chen A. Higman M, et al. Expert Opin Pharmacother. 2004 Dec;5(12):2605-13. doi: 10.1517/14656566.5.12.2605. Expert Opin Pharmacother. 2004. PMID: 15571477 Review.

Cited by

• Inpatient Management of Mucocutaneous GVHD.

  Vaidya T, Menzer C, Ponce DM, Markova A. Vaidya T, et al. Curr Dermatol Rep. 2019 Dec;8(4):258-278. doi: 10.1007/s13671-019-00280-3. Epub 2019 Nov 11. Curr Dermatol Rep. 2019. PMID: 33312761 Free PMC article.

• Treatment of steroid-refractory graft versus host disease in children.

  Gottardi F, Leardini D, Muratore E, Baccelli F, Cerasi S, Venturelli F, Zanaroli A, Belotti T, Prete A, Masetti R. Gottardi F, et al. Front Transplant. 2023 Sep 15;2:1251112. doi: 10.3389/frtra.2023.1251112. eCollection 2023. Front Transplant. 2023. PMID: 38993897 Free PMC article. Review.

• Risk and promise: an 11-year, single-center retrospective study of severe acute GVHD in pediatric patients undergoing allogeneic HSCT for nonmalignant diseases.

  Zaidman I, Even-Or E, Aharoni E, Averbuch D, Dinur-Schejter Y, NaserEddin A, Slae M, Shadur B, Stepensky P. Zaidman I, et al. Front Pediatr. 2023 May 26;11:1194891. doi: 10.3389/fped.2023.1194891. eCollection 2023. Front Pediatr. 2023. PMID: 37303759 Free PMC article.

• Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study.

  Greinix HT, Eikema DJ, Koster L, Penack O, Yakoub-Agha I, Montoto S, Chabannon C, Styczynski J, Nagler A, Robin M, Robinson S, Chalandon Y, Mikulska M, Schönland S, Peric Z, Ruggeri A, Lanza F, De Wreede LC, Mohty M, Basak GW, Kröger N. Greinix HT, et al. Haematologica. 2022 May 1;107(5):1054-1063. doi: 10.3324/haematol.2020.265769. Haematologica. 2022. PMID: 34162176 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wiley